We strive to provide the highest quality oligonucleotides to customers. To this end, we have partnered with Asahi Kasei Bioprocess. The result is a large-scale oligo synthesizer with innovations that improve and optimize the process of oligonucleotide synthesis. The synthesizer has been qualified for GMP batches.
One of the novel engineering solutions for our synthesizer is the in-line mixing of dichloroacetic acid (DCA) and toluene. The DCA-toluene solution is used in the first step for all coupling cycles of oligo synthesis. However, the percentage of DCA in toluene is fixed on most oligo synthesizers. With our new skid, there is the possibility to change the ratio of DCA in toluene. We customized our synthesizer with in-line mixing of DCA to adjust throughout the synthesis.
This innovation enables the correct amount of DCA to be transferred and avoids side reactions, providing a higher crude API quality.
Oligonucleotides - Innovation that transforms lives
More info on Oligo production at Bachem:
[ Ссылка ]
---------------------------------------------------------------------------------------------------------------------------
About Bachem:
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Learn more about our products and services at [ Ссылка ]
